



MEDIA RELEASE

For Immediate Release

Avellino Enters into Distribution Agreement With Keeler to Sell AvaGen, The Genetic Eye Test

Agreement allows licensed medical professionals to order AvaGen direct online

MENLO PARK, Calif. – (Jan. 18, 2022) – Avellino Lab USA, Inc. (Avellino) and Keeler, a global ophthalmic device manufacturer and distributor, have entered into an agreement where Keeler will distribute AvaGen™ on its US website.

AvaGen is the first genetic test that helps determine a patient's risk of keratoconus and the presence of TGFBI corneal dystrophies. The test allows for more confident management and treatment for patients with these conditions in order to protect and preserve patient vision. The test examines 75 keratoconus-related genes and more than 2,000 variants of those genes to develop an actionable genetic risk score for keratoconus.

“We are excited to partner with Keeler and provide expanded availability to this one-of-a-kind genetic test that can help earlier detect both keratoconus and certain corneal dystrophies,” says Avellino Global Head of Sales and Marketing Joe Boyd. “With these type of genetic conditions, early detection is key in protecting vision, and this new distribution channel will provide eye care professionals another way to access this groundbreaking test.”

“Keeler’s vision is ‘a world without vision loss,’ and AvaGen is a wonderful addition to our suite of products that supports our business strategy and goal to provide quality products to licensed medical professionals,” says Keeler Vice President of Business and Channel Management Eugene VanArsdale. “This will be the first ophthalmic genetic-based test we offer on our US website, and we are thrilled to offer the eye care community a new way to obtain this important diagnostic offering.”

AvaGen is expected to be available on the Keeler US website <https://www.keelerusa.com> by late January.

About Avellino

Avellino Lab USA, Inc. is a global leader in genetic molecular diagnostics at the forefront of precision medicine for eye care. With a long-term mission to develop personalized approaches to

better health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as genetic therapeutics leveraging CRISPR gene editing, to better manage and potentially cure inherited diseases. The company also developed the EAU-approved AvellinoSARS-CoV-2 RT-PCR diagnostic test to aid in COVID-19 pandemic testing efforts in the US, and was the third private company in the US to receive EUA for its COVID-19 test. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, China and the UK.

To learn more about Avellino, visit www.avellino.com.

About Keeler

Keeler is a world leader in ophthalmic diagnostic, digital, surgical, and clinical products. Keeler USA is the North America division, with headquarters, internal sales & marketing, manufacturing, warehouse and repair center, based in the Philadelphia area since the late 70s. Keeler USA manages sales, supply and maintenance to Canada, North America, Central America, Latin America and the Caribbean, both through regional and national distributors as well as through our own Regional and Internal Sales Managers, responsible for specific counties and states. Accutome's product lines of ultrasound equipment, clinical supplies, and diagnostic pharmaceuticals were merged into Keeler in 2017 to give a more robust equipment product offering as well as frequently used consumables that keep the company in close and constant contact with the eye care community.

Media Contact – Avellino

Angela Lapré
Global Head of Corporate Communications
Angela.Lapre@Avellino.com
650.788.0374

Media Contact – Keeler

Eugene R. VanArsdale
Vice President Business and Channel Management
evanarsdale@keelerusa.com
610.353.4350

###